Merck Reveals Mixed Data From Keytruda/Lynparza Regime In Ovarian Cancer

On Monday, Merck & Co Inc (NYSE:MRK) announced topline data from the Phase 3 KEYLYNK-001 trial.

The trial evaluating Keytruda (pembrolizumab) plus chemotherapy followed by maintenance with Lynparza (olaparib), with or without bevacizumab, as a first-line treatment for BRCA non-mutated advanced epithelial ovarian cancer met its primary endpoint of progression-free survival.

Also Read: Merck’s Multi-Billion Dollar Drug Keytruda’s Investigational Under The Skin Injection At Par With Intravenous Formulation In Untreated Lung Cancer Patients

At the final analysis conducted by an independent Data Monitoring Committee, the Keytruda plus Lynparza regimen demonstrated a statistically significant and clinically meaningful improvement in progression-free survival for these patients compared to chemotherapy alone.

The study did not reach its secondary endpoint of overall ...

Full story available on Benzinga.com